Mergers & acquisitions
Biogen announced it was exercising its option to participate in Genentech’s development of mosunetuzumab under a long-standing collaboration for antibodies targeting CD20.
Oxford BioMedica and Homology Medicines have formed a symbiotic partnership to launch a full scope AAV manufacturing and innovation business.
Biogen is selling its nearly 50% stake in Samsung Bioepis for $2.3 billion. The move will provide Biogen with additional capital while preparing to cut additional costs through a rumored employee layoff.
Fujifilm announced that it is acquiring Atara Biotherapeutics’ cell therapy manufacturing facility in California for $100 million.
Psychedelic-focused drug company Eleusis is merging with Silver Spike Acquisition Corp. II, a special purposes acquisition company, and heading to the Nasdaq with a combined enterprise value of $446 million.
Unilever announced Wednesday that it will not increase its bid over the recently proposed £50 billion (about $68 billion) to ensure that the acquisitions create value for its shareholders.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The company plans to use the money to boost its drug discovery pipeline in fibrosis and cancer and expand its team, facilities and operations.
UCB has announced that it is acquiring Zogenix as part of plans to expand its reach into commercializing and developing treatments for rare diseases.
Funds are always flowing in the life science industry. Here’s where the money’s headed this week.
PRESS RELEASES